IL-21 Promotes Skin Recruitment of CD4+ Cells and Drives IFN-γ–Dependent Epidermal Hyperplasia
Open Access
- 1 May 2011
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 186 (9) , 5435-5442
Abstract
Psoriasis is a chronic inflammatory disorder of the skin characterized by epidermal hyperplasia and infiltration of leukocytes into the dermis and epidermis. T cell-derived cytokines, such as IFN-γ and IL-17A, play a major role in the psoriasis-associated epidermal hyperplasia, even though factors/mechanisms that regulate the production of these cytokines are not fully understood. We have recently shown that IL-21 is synthesized in excess in psoriatic skin lesions and causes epidermal hyperplasia when injected intradermally in mice. Moreover, in the human psoriasis SCID mouse model, neutralization of IL-21 reduces both skin thickening and expression of inflammatory molecules, thus supporting the pathogenic role of IL-21 in psoriasis. However, the basic mechanism by which IL-21 promotes skin pathology remains unknown. In this study, we show that CD4+ cells accumulate early in the dermis of IL-21–treated mice and mediate the development of epidermal hyperplasia. Indeed, IL-21 fails to induce skin damage in RAG1-deficient mice and CD4+ cell-depleted wild-type mice. The majority of CD4+ cells infiltrating the dermis of IL-21–treated mice express IFN-γ and, to a lesser extent, IL-17A. Studies in cytokine knockout mice show that IFN-γ, but not IL-17A, is necessary for IL-21–induced epidermal hyperplasia. Finally, we demonstrate that IFN-γ–producing CD4+ cells infiltrating the human psoriatic plaque express IL-21R, and abrogation of IL-21 signals reduces IFN-γ expression in cultures of psoriatic CD4+ cells. Data indicate that IL-21 induces an IFN-γ–dependent pathogenic response in vivo, thus contributing to elucidate a mechanism by which IL-21 sustains skin-damaging inflammation.Keywords
This publication has 30 references indexed in Scilit:
- Skin-Resident T Cells: The Ups and Downs of On Site ImmunityJournal of Investigative Dermatology, 2010
- Skin immune sentinels in health and diseaseNature Reviews Immunology, 2009
- Interleukin-21 as a new therapeutic target for immune-mediated diseasesTrends in Pharmacological Sciences, 2009
- PsoriasisNew England Journal of Medicine, 2009
- Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathwaysBritish Journal of Dermatology, 2008
- IL-22 is required for Th17 cell–mediated pathology in a mouse model of psoriasis-like skin inflammationJournal of Clinical Investigation, 2008
- Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responsesJournal of Experimental Medicine, 2007
- IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesisJournal of Experimental Medicine, 2006
- Interleukin 21 Is a T Helper (Th) Cell 2 Cytokine that Specifically Inhibits the Differentiation of Naive Th Cells into Interferon γ–producing Th1 CellsJournal of Experimental Medicine, 2002
- Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes.Journal of Clinical Investigation, 1995